IDEAS home Printed from https://ideas.repec.org/
MyIDEAS: Log in (now much improved!)

Citations for "Representing uncertainty: the role of cost-effectiveness acceptability curves"

by Elisabeth Fenwick & Karl Claxton & Mark Sculpher

For a complete description of this item, click here. For a RSS feed for citations of this item, click here.
as in new window

  1. Stefano Conti & Karl Claxton, 2008. "Dimensions of design space: a decision-theoretic approach to optimal research design," Working Papers 038cherp, Centre for Health Economics, University of York.
  2. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347.
  3. Lars Oddershede & Simon Walker & Wolfgang Stöhr & David T. Dunn & Alejandro Arenas-Pinto & Nicholas I. Paton & Mark Sculpher, 2016. "Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial," PharmacoEconomics, Springer, vol. 34(8), pages 795-804, August.
  4. Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs, 2005. "Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 471-485.
  5. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
  6. Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir, 2008. "An assessment of the discriminative ability of the EQ-5D index , SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 237-249, August.
  7. Rachael L. Fleurence, 2007. "Setting priorities for research: a practical application of 'payback' and expected value of information," Health Economics, John Wiley & Sons, Ltd., vol. 16(12), pages 1345-1357.
  8. Martin Henriksson & Fredrik Lundgren & Per Carlsson, 2006. "Informing the efficient use of health care and health care research resources - the case of screening for abdominal aortic aneurysm in Sweden," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1311-1322.
  9. Mohan V. Bala & Gary A. Zarkin & Josephine Mauskopf, 2008. "Presenting results of probabilistic sensitivity analysis: the incremental benefit curve," Health Economics, John Wiley & Sons, Ltd., vol. 17(3), pages 435-440.
  10. Rob M.P.M. Baltussen & Raymond C.W. Hutubessy & Jan J. Barendregt & David B. Evans & Christopher J.L. Murray, 2003. "Formal response to 'Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues'," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 163-164.
  11. Casey Quinn, 2005. "Generalisable regression methods for costeffectiveness using copulas," Health, Econometrics and Data Group (HEDG) Working Papers 05/13, HEDG, c/o Department of Economics, University of York.
  12. Klemen Naveršnik, 2015. "Output correlations in probabilistic models with multiple alternatives," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 133-139, March.
  13. Elamin H. Elbasha, 2005. "Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 457-470.
  14. Douwe Postmus & Tommi Tervonen & Gert Valkenhoef & Hans Hillege & Erik Buskens, 2014. "A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 709-716, September.
  15. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333.
  16. David B. Evans & Dan Chisholm & Tessa Tan-Torres Edejer, 2012. "Generalized Cost-effectiveness Analysis: Principles and Practice," Chapters, in: The Elgar Companion to Health Economics, Second Edition, chapter 48 Edward Elgar Publishing.
  17. Sylvain Druais & Agathe Doutriaux & Magali Cognet & Annabelle Godet & Christophe Lançon & Pierre Levy & Ludovic Samalin & Pascal Guillon, 2016. "Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France," PharmacoEconomics, Springer, vol. 34(4), pages 363-391, April.
  18. Shiell, Alan & Rush, Bonnie, 2003. "Can willingness to pay capture the value of altruism? An exploration of Sen's notion of commitment," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 32(6), pages 647-660, December.
  19. Lisa Nagy & Terho Heikkinen & Alfred Sackeyfio & Richard Pitman, 2016. "The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland," PharmacoEconomics, Springer, vol. 34(9), pages 939-951, September.
  20. Jill Bindels & Bram Ramaekers & Isaac Corro Ramos & Leyla Mohseninejad & Saskia Knies & Janneke Grutters & Maarten Postma & Maiwenn Al & Talitha Feenstra & Manuela Joore, 2016. "Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives," PharmacoEconomics, Springer, vol. 34(3), pages 315-322, March.
  21. Rachel Elliott & Koen Putman & Matthew Franklin & Lieven Annemans & Nick Verhaeghe & Martin Eden & Jasdeep Hayre & Sarah Rodgers & Aziz Sheikh & Anthony Avery, 2014. "Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)," PharmacoEconomics, Springer, vol. 32(6), pages 573-590, June.
  22. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
  23. Mohsen Sadatsafavi; & Carlo Marra; & Lawrence McCandless & Stirling Bryan, 2012. "The challenge of incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods," Health, Econometrics and Data Group (HEDG) Working Papers 12/24, HEDG, c/o Department of Economics, University of York.
  24. Andrea Manca & Neil Hawkins & Mark J. Sculpher, 2005. "Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 487-496.
  25. Torbjørn Wisløff & Gunhild Hagen & Marianne Klemp, 2014. "Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation," PharmacoEconomics, Springer, vol. 32(6), pages 601-612, June.
  26. Elisabeth Fenwick & Bernie J. O'Brien & Andrew Briggs, 2004. "Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 405-415.
  27. J. Brown & N. J. Welton & C. Bankhead & S. H. Richards & L. Roberts & C. Tydeman & T. J. Peters, 2006. "A Bayesian approach to analysing the cost-effectiveness of two primary care interventions aimed at improving attendance for breast screening," Health Economics, John Wiley & Sons, Ltd., vol. 15(5), pages 435-445.
  28. Manca, A & Austin, P. C, 2008. "Using propensity score methods to analyse individual patient-level cost-effectiveness data from observational studies," Health, Econometrics and Data Group (HEDG) Working Papers 08/20, HEDG, c/o Department of Economics, University of York.
  29. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
  30. Baumann, Florian & Friehe, Tim, 2016. "Learning-by-doing in torts: Liability and information about accident technology," Economics Letters, Elsevier, vol. 138(C), pages 1-4.
  31. Raymond C. W. Hutubessy & Louis W. Niessen & Rob F. Dijkstra & Ton F. Casparie & Frans F. Rutten, 2005. "Stochastic league tables: an application to diabetes interventions in the Netherlands," Health Economics, John Wiley & Sons, Ltd., vol. 14(5), pages 445-455.
  32. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: The Elgar Companion to Health Economics, Second Edition, chapter 51 Edward Elgar Publishing.
  33. E. Remák & J. Hutton & M. Price & K. Peeters & I. Adriaenssen, 2003. "A Markov model of treatment of newly diagnosed epilepsy in the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(4), pages 271-278, December.
  34. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
  35. Miguel A. Negrín & Francisco J. Vázquez-Polo, 2006. "Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 363-372.
  36. Simon Eckermann & Andrew Willan, 2011. "Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies," PharmacoEconomics, Springer, vol. 29(7), pages 563-577, July.
  37. Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz, 2007. "Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 123-135, June.
  38. Douglas Coyle, 2003. "Determining the optimal combinations of mutually exclusive interventions: a response to Hutubessy and colleagues," Health Economics, John Wiley & Sons, Ltd., vol. 12(2), pages 159-162.
  39. Lagarde, Mylene & Blaauw, Duane & Cairns, John, 2012. "Cost-effectiveness analysis of human resources policy interventions to address the shortage of nurses in rural South Africa," Social Science & Medicine, Elsevier, vol. 75(5), pages 801-806.
This information is provided to you by IDEAS at the Research Division of the Federal Reserve Bank of St. Louis using RePEc data.